Q3 Earnings Estimate for Exelixis Issued By Leerink Partnrs

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Analysts at Leerink Partnrs lifted their Q3 2025 earnings estimates for shares of Exelixis in a note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst A. Berens now anticipates that the biotechnology company will post earnings per share of $0.61 for the quarter, up from their previous forecast of $0.60. The consensus estimate for Exelixis' current full-year earnings is $1.74 per share. Leerink Partnrs also issued estimates for Exelixis' Q4 2025 earnings at $0.67 EPS.

EXEL has been the subject of several other reports. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Exelixis in a research note on Thursday, February 13th. Royal Bank of Canada reissued an "outperform" rating and issued a $34.00 target price on shares of Exelixis in a research note on Wednesday, October 30th. Wells Fargo & Company raised their target price on shares of Exelixis from $32.00 to $36.00 and gave the company an "overweight" rating in a research note on Wednesday, October 30th. Stifel Nicolaus raised their target price on shares of Exelixis from $30.00 to $36.00 and gave the company a "hold" rating in a research note on Wednesday, February 12th. Finally, Guggenheim reissued a "buy" rating and issued a $42.00 target price on shares of Exelixis in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Exelixis presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.24.

Exelixis Price Performance

Shares of EXEL traded down $0.80 during mid-day trading on Friday, hitting $34.20. 2,492,716 shares of the company's stock were exchanged, compared to its average volume of 2,620,175. Exelixis has a 52 week low of $20.14 and a 52 week high of $37.59. The company has a 50-day simple moving average of $34.17 and a 200 day simple moving average of $31.08. The company has a market cap of $9.77 billion, a PE ratio of 21.92, a P/E/G ratio of 0.63 and a beta of 0.53.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 20.99% and a net margin of 22.43%.

Insider Buying and Selling at Exelixis

In related news, EVP Patrick J. Haley sold 10,000 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $35.27, for a total transaction of $352,700.00. Following the sale, the executive vice president now owns 278,665 shares in the company, valued at approximately $9,828,514.55. This trade represents a 3.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the business's stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the transaction, the executive vice president now owns 486,059 shares of the company's stock, valued at approximately $17,823,783.53. This represents a 10.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.85% of the company's stock.

Hedge Funds Weigh In On Exelixis

Several hedge funds and other institutional investors have recently modified their holdings of EXEL. Invesco Ltd. raised its position in Exelixis by 308.1% in the fourth quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company's stock valued at $132,376,000 after purchasing an additional 3,001,204 shares during the last quarter. Norges Bank bought a new position in Exelixis in the 4th quarter valued at approximately $94,867,000. Caisse DE Depot ET Placement DU Quebec raised its holdings in Exelixis by 330.4% in the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,484,395 shares of the biotechnology company's stock valued at $82,730,000 after buying an additional 1,907,167 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in Exelixis by 104.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company's stock worth $105,208,000 after buying an additional 1,613,482 shares during the period. Finally, Los Angeles Capital Management LLC grew its holdings in Exelixis by 124.0% during the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company's stock worth $46,473,000 after acquiring an additional 991,494 shares during the last quarter. Institutional investors own 85.27% of the company's stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.